At four-years-old, William Moore’s muscles are already beginning to deteriorate. Something as small as a slight gust of wind and sometimes even just thin air is enough to knock William over. Diagnosed ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, ...

Shareholder distributions are appropriate. Capital intensity of the industry remains low and gross margins high. In addition, Cochlear enjoys high cash conversion, enabling it to typically pay out 70% ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind ...

Total operating expenses for the fourth quarter of 2024 were $287 million, including non-cash stock-based compensation of $40 ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Unlike older male eye cells, which showed a consistent immune response pattern, older female eye cells appeared to experience ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...